Non-Profit Research
PharmBioTec gGmbH is a nonprofit organization dedicated to researching alternatives to animal testing. Our focus is on so-called New Approach Methodologies (NAMs), which include both ex vivo and in vitro methods for testing new drugs.
Our work is based on a large number of successfully completed research projects, as well as collaborations with companies and universities. Together, we develop innovative approaches for modern, animal-free research. Are you interested in a collaboration or a joint research project?
Our research and services
Preclinical research and fundamental questions
We are currently conducting research on the following two topics:
- Modeling human inflammatory diseases using cell models (EFRE project SaAr in vitro) (2024–2027)
- Investigation of new lectin-based formulations for the local treatment of herpes and Pseudomonas infections (EFRE cooperation project MucPower in collaboration with MucosaTec GmbH) (2025–2028)
The first results from “SaAr in vitro” have already been published:
Applied research with a focus on industrial applications
PharmBioTec gGmbH is working ton the development of innovative, animal-free methods for testing new formulations and active ingredients. For specific research questions, we can build on years of experience from our research projects:
- Innovative Monocyte-based Platform for Advanced Clinical Testing (INNO-KOM Project IMPACT) (2025–2028)
- 3T – Animal-Free Dry Powder Testing (Landesforschungsförderungsprogramm des Saarlandes) (2025)
- Topical formulation with the nanoscale-encapsulated active ingredients boswellic acid and EGCG for the treatment of psoriasis (ZIM project GreenCure) (2020–2022)
- Development of a Market-Ready Quality Control System for Determining Electrical Skin Resistance (ZIM Project SkinTER) (2022–2024)
- Collaborative Project: Development of a novel treatment for psoriasis based on a new target; subproject; development of methods for target validation and medicinal-chemical optimization of lead structures incorporating ADME testing (DLR/Eurostars-funded project PsoriaCure) (2020–2024)
- Animal-free testing of new pulmonary drug formulations (INNO-KOM project Kombipulmonal) (2020–2023)
- Topical formulation with the nanoscale-encapsulated active ingredients boswellic acid and EGCG for the treatment of psoriasis (ZIM project GreenCure) (2020–2022)
